ZyVersa Therapeutics, Inc. (OTCPK: ZVSA)
Health Care · Biotechnology · US
$0.10
+4.29% today · -23.4% 1Y
ZyVersa Therapeutics, Inc. (OTCPK: ZVSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $835.90K and employs 6 people.
Over the last twelve months the share price has lost 23.4%, trading between 0.08 and 0.30.
Tweenvest scores ZyVersa Therapeutics, Inc. across four factors: quality 8/100. Its strongest factor is quality.
ZVSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $835.90K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.40
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- $0.30
- 52-week low
- $0.08
- Avg volume (3M)
- —
- Shares outstanding
- 8.10M
- Employees
- 6
- Next earnings
- —
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
- ISIN
- US98987D3008
- Founded
- 2014
- Listed since
- Feb 11, 2022
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.82 | +1.02% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.72 | +0.41% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.58 | -0.09% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.55 | +0.06% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.78 | -4.34% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.